华润医药：华润医药(汕头)携华润双鹤等设立基金，聚焦合成生物学与创新药

Core Viewpoint - China Resources Pharmaceutical (03320.HK) announced the establishment of a proposed fund with a scale of RMB 500 million, focusing on high-growth investments in synthetic biology, innovative drugs, and biotechnology sectors [1] Group 1 - The fund will be established through a limited partnership agreement involving China Resources Pharmaceutical (Shantou) as the general partner, and China Resources Double Crane and China Resources Pharmaceutical Investment as limited partners [1] - The total commitment from the group will be RMB 123 million, representing approximately 24.6% of the total fund commitment [1] - Shenzhen China Resources Capital will be appointed as the fund manager [1]